<DOC>
	<DOC>NCT01344629</DOC>
	<brief_summary>To investigate the bioequivalence of telmisartan administrated in two different ways: both in telmisartan 80 mg/amlodipine 5 mg fixed-dose combination tablets (T) and as telmisartan 80 mg tablet and amlodipine 5 mg tablets (R) in concomitant use</brief_summary>
	<brief_title>Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg FDC Tablet and Telmisartan 80 mg Tab and Amlodipine 5 mg Tab Concomitant Use</brief_title>
	<detailed_description>Purpose:</detailed_description>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Inclusion criteria: 1. Without any clinically significant findings and complications on the basis of a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate, body temperature), 12lead electrocardiograms (ECGs), clinical laboratory tests 2. Age: =20 and =35 years 3. Body weight: =50 kg and =80 kg 4. Body mass index (BMI): =18.0 and =25.0 kg/m2 Exclusion criteria: 1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, or hormonal disorders 2. Diseases of the central nervous system (such as epilepsy) or psychiatric or neurological disorders 3. Chronic or relevant acute infections 4. Any clinical relevant findings in laboratory test results deviating from normal 5. A positive result in hepatitis B surface antigen (HBsAg), antihepatitis C virus (HCV) antibodies, a syphilis test, or an human immunodeficiency virus (HIV) test 6. History of surgery of the gastrointestinal tract (except appendectomy) 7. History of relevant orthostatic hypotension, fainting spells, or blackouts 8. Known hypersensitivity to any component of the formulation (telmisartan and amlodipine), to any other angiotensin receptor blocker, or to any other dihydropyridine calcium channel blocker compound 9. Intake of drugs with a long halflife (=24 hours) within at least 1 month or less than 10 halflives of the respective drug before drug administration 10. Intake of drugs which might reasonably influence the results of the trial on the basis of the knowledge at the time of protocol preparation within 7 days before drug administration 11. Participation in another trial with an investigational drug within 1 months or less than 10 times of halflives of the investigational products before drug administration 12. Smoker (=20 cigarettes/day) 13. Alcohol abuse (60 g or more ethanol/day: e.g., 3 middlesized bottles of beer, 3 gous [equivalent to 540 mL] of sake) 14. Drug abuse 15. Blood donation (more than 100 mL within 4 weeks before drug administration) 16. Excessive physical activities (ex. Marathon etc) within 1 week before drug administration 17. Intake of alcohol within 2 days before drug administration 18. Inability to comply with dietary regimen of the study site 19. Inability to refrain from smoking during trial days</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>